Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)
Exercise of Options
London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercise price of GBP1.26 per share on 1 April 2015.
Following the issue of the Shares, which are expected to be held as a long term investment by Mr Cheng, Mr Cheng is beneficially interested in 256,146 Shares, representing 0.48% of the current issued share capital of Chi-Med.
Ends
Enquiries
Chi-Med Christian Hogg, CEO |
Telephone: +852 2121 8200
|
|
|
Panmure Gordon (UK) Limited |
Telephone: +44 20 7886 2500 |
Richard Gray Andrew Potts |
|
|
|
Citigate Dewe Rogerson Anthony Carlisle David Dible |
Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.